CD34+CD38−CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection

Abstract

Background/Aims

In CD34-positive acute myeloid leukaemia (AML), the leukaemia-initiating event likely takes place in the CD34+CD38− cell compartment. CD123 has been shown to be a unique marker of leukaemic stem cells within the CD34+CD38− compartment. The aim of this study was to identify the percentage of CD34+CD38−CD123+ cells in AML blasts, AML CD34+CD38− stem cells, and normal and regenerating bone marrow CD34+CD38− stem cells from non-myeloid malignancies.

Methods

Thirty-eight adult de novo AML patients with intention to treat were enrolled after the application of inclusion criteria from February 2012 to February 2017. The percentage of the CD34+CD38−CD123+ phenotype in the blast population at diagnosis was determined using a CD45-gating strategy and CD34+ backgating by flow cytometry. We studied the CD34+CD38−CD123+ fraction in AML blasts at diagnosis, and its utility as a unique phenotype for minimal residual disease (MRD) of AML patients.

Results

CD123+ cells were present in 97% of AML blasts in patients at diagnosis (median 90%; range 21–99%). CD123+ cells were also present in 97% of the CD34+CD38− compartment (median 0.8164%, range 0.0262–39.7%). Interestingly, CD123 was not present in normal and regenerating CD34+CD38− bone marrow stem cells (range 0.002– 0.067 and 0.004–0.086, respectively).

Conclusion

The CD34+CD38−CD123+ phenotype is present in virtually all AML blasts and it may be used as a unique single phenotype for MRD detection in AML patients.

Introduction

Acute myeloid leukaemia (AML) is a clonal haemopoietic stem cell disorder in which increased proliferation and failure of differentiation in the stem cell compartment results in the accumulation of non-functional immature cells termed myeloblasts. AML accounts for approximately 25% of all leukaemias and is the most common form of acute leukaemia seen in adults [1]. A study of 64 European population-based cancer registries revealed that AML accounts for 43% of all myeloid malignancies estimated to occur annually in Europe [2]. Important advances in therapy and supportive care over the past 3 decades have led to the improved survival of patients with AML [3]. However, despite high complete remission (CR) rates being achieved with modern induction chemotherapy, overall survival (OS) remains at only about 50% for those who achieve CR, or 26% overall [4, 5]. Alarmingly, the average OS rates for men and women in Europe are 15 and 18%, respectively [6]. The outcome for adults with AML depends upon a number of well-defined prognostic markers, such as age, white cell count, cytogenetics, molecular mutations, and whether the AML is de novo or secondary in origin [7, 8, 9].

Multiparameter flow cytometry has many advantages over morphology as it is very sensitive: it can detect 1 cell in a background of 10⁵ or 10⁶ cells, it is relatively cheap and quick, and can detect abnormal cells with high specificity. Hence, it is an important tool for detecting a very low number of abnormal cells at diagnosis and after chemotherapy [10, 11].

Human AML stem cells have been defined as CD34+CD38− cells with a severe combined immunodeficient-repopulating ability, which is a reflection of their capacity to self-renew [12]. In contrast, mature CD34+CD38−/high⁺ leukaemia cells failed, under appropriate conditions of transplantation, to differentiate and cause an AML malignant transformation [13].

The IL-3 receptor α chain (CD123) has been suggested to be a marker of leukaemic stem cells (LSCs) [14, 15]. These cells are thought to be responsible for initiating and maintaining leukaemic cell growth following chemotherapy and hence give rise to relapse of the disease. It is hypothesised that CD34+CD38−CD123+, which has been identified as a possible putative marker or phenotype of the LSC, could be a useful unique phenotype that can predict an adverse outcome [16]. Previous studies have shown that the LSCs with the CD34+CD38−CD123+ phenotype were preferentially residing in a bone marrow endosteal region niche in a quiescent state untouched by chemotherapy [17, 18]. Enrichment of these chemoresistant cells within this leukaemic compartment supports the theory behind the occurrence of relapse in CR patients [16]. This justifies tracking this particular compartment to assess its clinical utility in AML and minimal residual disease (MRD) monitoring.

The aim of this study was to identify the level of expression of CD123 on total AML blast populations, and LSCs as defined by CD34+CD38− at diagnosis in AML patients. In addition, we also identified the level of expression of CD123 on stem cells as defined by CD34+CD38− in normal bone marrow and regenerating bone marrow with non-myeloid malignancies postchemotherapy to determine the specificity of this phenotype.

Materials and Methods

Samples

Fresh bone marrow samples from adult consecutive, unselected, newly diagnosed, de novo AML patients with intention to treat were enrolled from The Royal Hospital and Sultan Qaboos University Hospital from February 2012 to February 2017. Samples were included in the study after applying the inclusion criteria.

Study Conduct

The study was approved by the Medical Ethics and Scientific Research Committee (MESRC) of the Royal Hospital, the Sultan Qaboos University Medical Research Committee, and the Research and Ethical Review and Approval Committee (RERAC) of the Ministry of Health prior to its initiation. An informed written consent at diagnosis was taken from all patients who were enrolled into the study.

Criteria for Inclusion

For inclusion in this study, a confirmed diagnosis of AML (based on morphology, immunophenotyping, and cytogenetics) and an expression of CD34+ cells were required. Thirty-eight patients were enrolled in the study after application of the inclusion criteria.

The gender, age, WBC count, blasts percentage at diagnosis, clinical cytogenetics, and molecular mutation (FLT3/ITD and NPM1) status were studied for each patient.

Controls (Normal Bone Marrow and Regenerating Bone Marrow)

Normal bone marrow from 5 healthy volunteers and regenerating bone marrow from 5 patients with non-myeloid malignancies treated with chemotherapy were used as controls. The expression of CD123 on CD34+CD38− cells of the normal and regenerating bone marrow was investigated.

Expression of CD123 (IL-3 Receptor) in Total AML CD34+ Blasts and CD34+CD38− AML Stem Cells

Immunophenotypic analysis was performed on erythrocyte-lysed whole bone marrow samples from the newly diagnosed adult AML patients. Directly conjugated monoclonal antibodies to CD34, CD38, CD45, and CD123 were used to characterise LSC. Blasts were identified by the CD45/SS log gating strategy with backgating strategies using CD34 to better define the blast population (Fig. 1). Appropriate isotype-matched negative controls were used to assess the background fluorescence intensity. The percentage of CD123 was determined on the total AML blast cells expressing CD34+. Using the same gating strategy as shown in Figure 2, the expression of CD123 was determined on the LSC population defined by the phenotype CD34+CD38−.

Fig. 1.

CD34+ backgating strategy to identify the blast population.

Fig. 2.

Gating strategy in newly diagnosed AML to identify CD34+CD38−CD123+ cells [30]. a Ungated: to identify the blast population based on CD45 dim and low SS log and CD34 backgating. b Ungated: to identify CD34+ cells and the blast population on the CD45/SSC log density plot. c Gated on CD34+ cells: to identify a population homogenous for CD34+ cells. d Ungated: to identify CD34+ cells which resemble the blast populations. e Ungated: to identify a CD38+ population from the total population. f Ungated: to identify a CD123+ population from the total population. g Dot plot: gated on CD34+ homogenous cells. h Density plot: gated on CD34+ homogenous cells. i Density plot: gated on CD34+CD38− cells to identify a population homogenous for the scatter. j Dot plot: gated on CD34+CD38− homogenous cells. k Density plot: gated on CD34+CD38− homogenous cells. l Density plot: gated on CD34+CD38− homogenous cells to identify a population homogenous for the scatter.

Analysis

Cells were analysed on a Cytomics FC500 flow cytometer (Beckman Coulter) and Kaluza Software (version 1.3; Beckman Coulter). Thresholds for positivity were based on isotype controls with a positivity threshold of 20% for all markers. For all samples, not less than 25,000 events were acquired and not less than 20 events in a cluster were considered as positive.

Quality Control

Internal quality control procedures were used to assess the instrument parameters and ensure accurate results. Daily calibration of the flow cytometer was performed for optical laser alignment and optimal hydrodynamic focussing settings. An external quality assurance procedure was also implemented through participation in a performance-monitoring network operated by the Royal College of Pathologists of Australasia Quality Assurance (RCPA) programme. The Royal Hospital is covered under the Canadian Qmentum International Accreditation with the laboratory also being covered by the UKAS Medical Laboratory accreditation (ISO 15189).

Results

The main demographic characteristics of patients (gender, median age, WBC count at diagnosis, cytogenetic risk group, FLT3-ITD and NPM1 mutations) are shown in Table 1. The median age of our cohort was 45 years (range 15–82) and the median WBC count (×10⁹/L) at diagnosis was 29.7 (range 1.2–234).

Table 1.

Characteristics of the 38 AML patients at diagnosis

Patients, n	38
Male/female, n	22/16
Age at diagnosis, years	45 (15–82)
WBC at diagnosis, ×109/L	29.7 (l.2–234)
Blasts at diagnosis by flow cytometry, %	63.5 (23–95)
Cytogenetic risk group
Favourable	6 (16)
Intermediate	22 (58)
Poor	3 (8)
Could not be analysed	7 (18)
FLT3-ITD mutation
Positive	10 (26.3)
Negative	26 (68.4)
Could not be analysed	2 (5.3)
NPM1 mutation
Positive	2 (5.3)
Negative	27 (81.6)
Could not be analysed	5 (13.1)

Data are presented as n (%) or median (range).

Expression of CD123 (IL-3 Receptor) in Total AML CD34+ Blasts

CD45 staining and side scatter log properties were used to isolate blasts after optimisation through a backgating strategy using CD34 (the marker found positive on blasts), as shown in Figure 1. The percentage of CD123+ cells were then quantified on the AML blasts. CD123 was found to be expressed in 37 (97%) out of the 38 AML cases analysed. The median expression of CD123 was 90% (range 21–99%).

Expression of CD123 (IL-3 Receptor) in CD34+CD38− AML Stem Cells

The percentage of CD34+CD38−CD123+ cells quantified by sequential gating is shown in Figure 2. CD123 was expressed on CD34+CD38− AML stem cells in 37 (97%) out of the 38 AML patients. The percentage of CD34+CD38−CD123+ cells at diagnosis ranged from 0.0262 to 39.7% (median 0.8164, mean 4.45)

Expression of CD123 (IL-3 Receptor) in CD34+CD38− Normal Bone Marrow and Regenerating Bone Marrow

CD123 was not present in CD34+CD38− normal bone marrow stem cells (range 0.002–0.067%, n = 5). Interestingly, CD123 was also not present in CD34+CD38− regenerating bone marrow stem cells (range 0.004–0.086, n = 5)

Discussion

Relapse of AML starts with leukaemic cell expansion arising from the AML stem cells [19]. In AML, the stem cells are contained within a population of CD34+ and CD38- cells. Since about 50% of patients in CR will eventually experience a relapse [4], a more defined assessment of the quality of CR is important for prognostic purposes. It is thus vital to be able to identify and enumerate the leukaemic cell subpopulation present in the CD34+CD38− fraction that is in a quiescent state and highly resistant to chemotherapy, which is ultimately responsible for the emergence of relapse. The high-affinity IL-3 receptor α, CD123, is a target expressed on the surface of AML LSCs with the capacity to identify and enumerate this leukaemic subpopulation [20].

Our study confirmed the expression of CD123 as being present in virtually all AML blasts (97%). It also demonstrated that CD123 is present in the majority (97%) of AML stem cell CD34+CD38− compartments. The percentage of CD34+CD38−CD123+ cells at diagnosis on AML blasts ranged from 0.02 to 39%. Vergez et al. [16] reported similar levels of CD34+CD38−CD123+ cells using multiparameter flow cytometry with the percentages of leukaemic cells ranging from 0.01 to 67% [16, 21].

Interestingly, our study showed that CD123 is not present in either normal bone marrow or regenerating bone marrow. This ability of CD123 to discriminate between normal cells and LSCs means it is a highly specific and unique marker with the possibility to define MRD using CD34+CD38−CD123+ as a phenotype to detect populations containing LSC [15, 22, 23]. This approach would use a much smaller number of antigens and antigen combinations, resulting in relatively simple data interpretation. It could be a useful prognostic indicator at diagnosis as current chemotherapeutic approaches do not target these cells [24, 25, 26].

Our study also showed that 26% of our AML cohort had the FLT3/ITD mutation. Clinical data suggest that poorer prognosis is related to the presence and sizes of FLT3/ITDs in AML [27, 28, 29]. Nine cases (24%) of the 37 CD123+ AML were FLT3/ITD positive, which reiterates the possibility of an enhanced survival of FLT3/ITD AML LSCs. This was further supported by our recent finding that FLT3/ITD mutations are present at the LSC level, which also showed that the oncogenic events of FLT3/ITD occurred at a cell stage possessing the IL-3 receptor α (CD123) [30]. This correlation forms a basis for CD123-targeted therapies in AML with intracellular FLT3 inhibitors [31].

A number of studies suggest that targeting of the CD123/IL-3 receptor α may be a novel and promising treatment approach in patients with CD123+ AML [32, 33, 34]. This concept is based on the notion that myeloblasts express CD123 in most patients with AML, as shown in our study. Our results demonstrate the utility of CD34+CD38−CD123+ cells, which may be used as the basis of risk-stratified AML clinical trials. Previous studies have shown that high levels of CD34+CD38− stem cells at diagnosis, as well as high levels of CD34+CD38+CD123+ cells, are predictive of high MRD and an adverse outcome in terms of relapse-free survival and OS [16, 35]. Recent studies have shown anti-CD123 antibodies as targets against AML LSCs. Adams et al. [36] showed that IMGN632, a CD123-targeting antibody drug conjugate, was highly potent in vitro against CD123-expressing human AML cell lines with prolonged survival in immunodeficient mice. A phase 1 study of CSL362, another anti-CD123 antibody, showed the potency and specific targeting of normal cells expressing high CD123 in AML patients in CR at high risk for early relapse [37]. These promising CD123-targeing studies emphasise the importance of evaluating the CD34+CD38−CD123+ fraction in AML patients. Considering the use of CD123-targeted drugs in AML, it is of particular importance to identify that these cells express leukaemia-specific molecular abnormalities, such as FLT3 mutations.

Eradication of malignant stem cells can probably be achieved in some patients using conventional chemotherapy through the application of repetitive cycles of consolidation therapy [38]. However, given that LSCs are contained within the CD34+CD38−CD123+ population in AML and the apparent difficulties in eradicating malignant cells from the patient, it will be necessary to develop therapies that specifically target the malignant stem cells of this phenotype after reaching CR. The possibility to detect and characterise stem cells will help in reaching this goal.

In the future, it would be of great interest to study the frequency of CD34+CD38−CD123+ cells during follow-up as these cells may represent the highly resistant cells to chemotherapy and might be the cells that cause regrowth of leukaemia and thus relapse of the disease. In principle, this would allow us to correlate the LSC frequency at diagnosis with LSC frequency in CR after chemotherapy. It would be of value to study if the prognostic impact of the MRD stem cell frequency might improve the already strong impact of total MRD frequency in leukaemia-associated phenotypes on outcome. Apart from the leukaemia-associated phenotype expression, the LSC selective expression of CD123 and of the recently described CLL-1 [39, 40] should be very helpful in this respect.

Conclusion

Our study shows that the CD34+CD38−CD123+ phenotype is present in virtually all AML blasts and it may be used as a unique single phenotype for MRD detection in AML patients. MRD will significantly improve the evaluation of the prognosis of patients with AML and ultimately play a major role as a stratification parameter to guide the risk-adapted therapy of the disease. With the functional and phenotypic properties of LSCs being further explored, these cells appear to be the most important target cell population in the context of curative therapies [41, 42]. Therefore, the potent anti-leukaemic effects of “stem cell-targeted” drug therapy is a very promising approach for the future. Whether these strategies will help in the eradication of AML clones and the management of minimal residual AML remains to be determined in future clinical trials.

Disclosure Statement

The authors declare no conflicts of interest.

Funding Sources

This work was supported by The Research Council (TRC), Oman (grant No. 47).